Vertex Pharmaceuticals (VRTX) valuation history
Above its usual range
As of
VRTX's EV/Sales of 10.0x is higher than 74% of its available weekly readings from the last five years.
Share EV/Sales history
Chart by stockresearch.app. Reuse with credit under CC BY 4.0.
EV/Sales at year-end
Last weekly reading of each completed year. Rank runs from lowest (0%) to highest (100%) within the five years available on that date.
| Reading date | EV/Sales | 5-year rank |
|---|---|---|
| 9.4× | 67% | |
| 9.4× | 63% | |
| 9.8× | 64% | |
| 7.5× | 16% | |
| 7.0× | 9% | |
| 9.4× | 4% | |
| 14.6× | 30% | |
| 14.8× | 25% | |
| 15.6× | 50% | |
| 10.2× | 27% |
Loading related research…
About this history
- What is VRTX's current EV/Sales?
- VRTX's EV/Sales of 10.0x is higher than 74% of its available weekly readings from the last five years.
- What is VRTX's five-year median EV/Sales?
- The median, or middle weekly reading, is 8.9× over the last five years. Available history contains 818 weekly observations from Feb 21, 2011 to Oct 19, 2026.
- Does a low historical rank mean a stock is a buy?
- No. The rank describes a stock’s own history. Changes in growth, financial risk and the business can change the multiple investors pay. P/E uses earnings and P/S uses revenue from the previous twelve months.